EUVIMEDEUVIMED entdecken
Open Access

Removing the FDA’s Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan

William B Feldman, Mufaddal Mahesri, Ameet Sarpatwari, Krista F Huybrechts, Yanmin Zhu, Catherine S Hwang, Joyce Lii, Su Been Lee, Sushama Kattinakere Sreedhara, Gita A Toyserkani, Esther H Zhou, Laura Zendel und 5 weitere

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.19873 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von William B Feldman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass…. Hauptthemen laut MEDLINE: Phenylpropionates, Pyridazines, Liver Function Tests, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, FDA HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Endothelin receptor antagonists are first-line therapy for pulmonary arterial hypertension (PAH). The first 2 agents approved in the class, bosentan and ambrisentan, initially carried boxed warnings for hepatotoxicity and required monthly liver function tests (LFTs) as part of a risk evaluation and mitigation strategy (REMS); however, in 2011, as further safety data emerged on ambrisentan, the boxed hepatotoxicity warning and LFT requirements were removed.

Objective

To analyze changes in the use of and LFT monitoring for ambrisentan and bosentan after changes to the ambrisentan labeling and REMS. Design, Setting, and Participants This serial cross-sectional study used data from 3 longitudinal health care insurance claims databases—Medicaid, Optum’s deidentified Clinformatics Data Mart, and Merative Marketscan—to perform an interrupted time series analysis of prescription fills and LFTs for patients taking ambrisentan and bosentan. Participants were patients filling prescriptions for ambrisentan and bosentan from July 1, 2007, to December 31, 2018. Data analysis was performed from April 2021 to August 2023. Exposure Removal of the boxed warning for hepatotoxicity and the REMS LFT monitoring requirements on ambrisentan in March 2011. Main Outcomes and Measures The primary outcomes were use of ambrisentan (ie, individuals with at least 1 dispensing per 1 000 000 individuals enrolled in the 3 datasets) vs bosentan and LFT monitoring (ie, proportion of initiators with at least 1 ordered test) before initiation and before the first refill.

Results

A total of 10 261 patients received a prescription for ambrisentan during the study period (7442 women [72.5%]; mean [SD] age, 52.6 [17.6] years), and 11 159 patients received a prescription for bosentan (7931 women [71.1%]; mean [SD] age, 47.7 [23.7] years). Removal of the ambrisentan boxed hepatotoxicity warning and LFT monitoring requirement was associated with an immediate increase in the use of ambrisentan (1.50 patients per million enrollees; 95% CI, 1.08 to 1.92 patients per million enrollees) but no significant change in the use of bosentan. There were reductions in recorded LFTs before drug initiation (13.1% absolute decrease; 95% CI, −18.2% to −8.0%) and before the first refill (26.4% absolute decrease; 95% CI, −34.4% to −18.5%) of ambrisentan but not bosentan. Conclusions and Relevance In this serial cross-sectional study of ambrisentan, labeling changes and removal of the REMS-related LFT requirement were associated with shifts in prescribing and testing behavior for ambrisentan but not bosentan. Further clinician education may be needed to maximize the benefits of REMS programs and labeling warnings designed to ensure the safe administration of high-risk medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylpropionatesPyridazinesLiver Function TestsChemical and Drug Induced Liver InjuryBosentanHumansFemaleMaleMiddle AgedCross-Sectional StudiesUnited StatesAdultDrug LabelingUnited States Food and Drug AdministrationAntihypertensive AgentsAgedEndothelin Receptor AntagonistsHypertension, Pulmonary

Substanzen

ambrisentanPhenylpropionatesPyridazinesBosentanAntihypertensive AgentsEndothelin Receptor Antagonists

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

Förderung

  • NIA NIH HHS
  • FDA HHS
  • NHLBI NIH HHS

Zitieren

APA

Feldman, W. B., Mahesri, M., Sarpatwari, A., Huybrechts, K. F., Zhu, Y., Hwang, C. S., Lii, J., Lee, S. B., Kattinakere Sreedhara, S., Toyserkani, G. A., Zhou, E. H., Zendel, L., LaCivita, C., Manzo, C., Dal Pan, G. J., Kesselheim, A. S., & Bykov, K. (2024). Removing the FDA’s Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.19873

Vancouver

Feldman WB, Mahesri M, Sarpatwari A, Huybrechts KF, Zhu Y, Hwang CS, et al. Removing the FDA’s Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.19873

BibTeX
@article{Feldman2024,
  author = {Feldman, William B and Mahesri, Mufaddal and Sarpatwari, Ameet and Huybrechts, Krista F and Zhu, Yanmin and Hwang, Catherine S and Lii, Joyce and Lee, Su Been and Kattinakere Sreedhara, Sushama and Toyserkani, Gita A and Zhou, Esther H and Zendel, Laura and LaCivita, Cynthia and Manzo, Claudia and Dal Pan, Gerald J and Kesselheim, Aaron S and Bykov, Katsiaryna},
  title = {Removing the FDA’s Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.19873}
}
Kostenlos starten →